Genomtec S.A. (WSE: GMT)
Poland flag Poland · Delayed Price · Currency is PLN
7.70
+0.20 (2.67%)
Sep 27, 2024, 5:00 PM CET

Genomtec Income Statement

Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
-0.0900.040.220.02
Revenue Growth (YoY)
--97.50%-81.74%995.00%-
Cost of Revenue
1.180.793.275.383.53
Gross Profit
-1.27-0.79-3.23-5.16-3.51
Selling, General & Admin
9.859.438.575.3610.97
Other Operating Expenses
-1.82-1.5-0.31-3.53-3.62
Operating Expenses
8.037.938.261.837.36
Operating Income
-9.31-8.73-11.49-7-10.86
Interest Expense
-0.12-0.12-0.2-0.03-0.02
Interest & Investment Income
0.01---0
Currency Exchange Gain (Loss)
-0.11-0.13-0.1-0.09-0.06
Other Non Operating Income (Expenses)
-0.06-0.05-0.09--0
Pretax Income
-9.59-9.03-11.88-7.11-10.94
Income Tax Expense
--0.020.050.010
Net Income
-9.59-9.01-11.93-7.12-10.94
Net Income to Common
-9.59-9.01-11.93-7.12-10.94
Shares Outstanding (Basic)
1312988
Shares Outstanding (Diluted)
1312988
Shares Change (YoY)
27.53%30.90%14.78%--
EPS (Basic)
-0.75-0.74-1.27-0.87-1.34
EPS (Diluted)
-0.75-0.74-1.27-0.87-1.34
Free Cash Flow
-6.02-11.48-7.93-5.71-2.63
Free Cash Flow Per Share
-0.47-0.94-0.85-0.70-0.32
Operating Margin
--872700.00%-28730.00%-3194.06%-54315.00%
Profit Margin
--901300.00%-29820.00%-3248.86%-54695.00%
Free Cash Flow Margin
--1147900.00%-19822.50%-2608.68%-13135.00%
EBITDA
-7.68-7.57-11.06-6.49-10.62
D&A For EBITDA
1.621.160.440.50.24
EBIT
-9.31-8.73-11.49-7-10.86
Source: S&P Capital IQ. Standard template. Financial Sources.